The Technical AnalystExchange: TAI Sector: Healthcare Industry: Biotechnology
Adimmune Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% TWD27.60
America/New_York / 3 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11 854 mill |
| EPS: | -1.520 |
| P/E: | -18.16 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 429.51 mill |
| Avg Daily Volume: | 1.152 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -18.16 | sector: PE 18.55 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.33x |
| Company: PE -18.16 | industry: PE 13.63 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
TWD 27.25 - 27.95 ( +/- 1.28%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD27.60 (0.00% ) |
| Volume | 0.472 mill |
| Avg. Vol. | 1.152 mill |
| % of Avg. Vol | 41.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4142.TW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4142.TW
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.